Sexually transmitted and blood-borne infections

Given the desire to harmonize medical and nursing practices in the field of sexually transmitted infections (STIs) and the need to provide better guidance on the intervention known as expedited partner therapy (EPT), the Institut national de santé publique du Québec received a request from the Collège des médecins du Québec and the Ministère de la Santé et des Services sociaux. The purpose of…

A lot of new data on the immunogenicity, efficacy and effectiveness of fewer than three doses of HPV vaccine have become available since the publication of the CIQ report on the 2012 knowledge update. The two-dose schedule has become a standard that is widely accepted around the world. Such schedules are currently in use in more than half (48/82) of the countries offering HPV vaccination…

A more recent publication based on new studies has just been issued by the Ministère de la Santé et des Services sociaux. This update is titled «L'effet du traitement des personnes vivant avec le VIH sur le risque de transmission sexuelle de l'infection» (The impact of treating people living with HIV on the risk of sexual transmission of the…

In Nunavik, the battle against bacterial sexually transmissible and blood-borne infections (STBBIs) has become increasingly urgent. In the wake of mass interventions in the 1990s, and despite more recent efforts, the region has been unable to lower its incidence curves, particularly for gonococcal infection, which has reached epidemic proportions since fall 2007. In this context, and spurred…

In 2007, the Comité sur l’immunisation du Québec (CIQ) recommended an extended schedule exclusively for immunization against the human papilloma virus (HPV) starting in grade 4 (0, 6, 60 months); the committee also stated that the third dose should be administered “if judged necessary.” Since the introduction of the Québec HPV immunization program in 2008, similar programs (two doses…

The human papillomavirus (HPV) belongs to the Papillomaviridae family, which includes at least 100 genotypes affecting the skin and mucous membranes. Of these, about 40 affect the anogenital area in particular, and approximately 15 are oncogenic. Genotypes 16 and 18 are responsible for 70-76% of cervical cancer cases worldwide. Genotypes 6 and 11 are non-oncogenic but are…

Since 2000, the resurgence of syphilis in Québec has led to increased screening and resulted in a greater number of reported cases, particularly in the Montréal area. To meet the growing demand for laboratory testing, some medical diagnostic laboratories have introduced an enzyme immunoassay (EIA) test into their syphilis detection algorithm. This situation raised concerns among general…

Given that certain questions have been raised regarding the results of studies on the effects of SISs, the Institut national de santé publique du Québec (INSPQ) has taken the initiative of carrying out a critical analysis of these studies.

The objective of this report is to evaluate the relevance of establishing supervised injection sites in the province of Québec. It is based on a…

In October 2007, the Comité sur l'immunisation du Québec (CIQ) tabled a report entitled “Prévention par la vaccination des maladies attribuables aux virus du papillome humain au Québec” [Prevention of diseases caused by human papillomaviruses through vaccination]. At the time that report was being drafted, only one vaccine – Gardasil – was authorized for sale in Canada. The report did not…

This paper describes the state of health of Nunavik Inuit women and the sexual health profile of men and women as reported during the Nunavik Inuit Health Survey 2004. The results focus on the preventive attitude among women such as screening techniques of cervical and breast cancer and also on women’s behaviour during pregnancy and their bone health status. It also concentrates on preventive…